Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues

Vertex Pharmaceuticals has ridden a powerful five year share price run while pushing deeper into kidney disease, endocrinology and pain treatments, which puts fresh attention on what investors are really paying for its cash flows today. With the stock near recent highs after a series of clinical and commercial updates, the open question is whether the current market price lines up with the cash the business is expected to generate over time. Over the past 5 years, Vertex Pharmaceuticals has...